Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus ARAZLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus ARAZLO.
ALA-SCALP vs ARAZLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Topical application of a 5% solution to the scalp twice daily.
Topical: Apply 0.045% gel once daily to affected areas of the face.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid